Excellent talk by Dr. Anna Molto. Characteristics of spondyloarthritis, noting some patients with PsA have radiographic and non-radiographic axial SpA. #ACR21 6S403 @RheumNow https://t.co/ycftOMrWO9

Are we getting closer to personalised medicine in #psoriaticarthritis Predicting progressors vs non-progressors using proteomics identified 103 candidate biomarker peptides that will discriminate the two groups @RheumNow #ACR21 #ACRBest Abst#0449 https://t.co/obDXTz3i5N

• Identification of Serum Protein Biomarkers at Baseline to Distinguish Radiograp…

Excellent scientific session on #SpA at #ACR21 right now- especially like this clear diagram of pathophysiology and useful summary slide from Dr Nigil Haroon on differences between #axSpA and axial #PsA @RheumNow https://t.co/F7Ns7e9HQI

“The differences and similarities between axial disease in psoriatic arthritis vs axial spondyloarthritis is just at the cusp of discovery” Nigil Haroon at session 6S403 @RheumNow #ACR21

Tyk2/Jak1 inhibitor brepocitinib in PsA. Looks good. Works for skin, joints, enthesitis, dactylitis, and PROs. No unexpected safety signals. Abstr#0488 #ACR21 @RheumNow https://t.co/MIOLw8BABN

Risankizumab (IL-23i) KEEPsAKE 1 and 2 (phase 3) studies for PsA treatment ⬆️ACR20 response compared to pbo ⬆️secondary endpoints ⭐️no new safety signals Abs#453 #ACR21 #ACRBest @RheumNow https://t.co/7bwvIPMz38 https://t.co/TJaSqwipa5

• Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Int…

#ACR21 #ACRBest @Rheumnow Abst #0452 Raychaudhuri et al. TB-PET/CT indices ➡️ disease outcome measures in PsA Identifies synovitis, enthesitis, dactylitis, nail matrix inflammation of PsA as compared to RA and OA Future use as a diagnostic tool for early disease of PsA https://t.co/uLsAWEkboS

Can we predict who which PsA pts will be radiographic progressors? Abs#449 identified 103 candidate biomarker peptides corresponding to 69 proteins that could ID progressors More data needed #ACR21 @RheumNow https://t.co/OLfPRNjTKV https://t.co/6UTn1J7nJH

• Identification of Serum Protein Biomarkers at Baseline to Distinguish Radiograp…

New treatments in #psoriaticarthritis Brepocitinib TYK 2/JAK 1 inhibitor had superior efficacy vs PBO in active PsA at Week 16, with improvements in more refractory domains over 52 weeks. Safety consistent with other JAKi @RheumNow #ACR21 Abstr#0488 https://t.co/ugsV7uRwro

• Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor…

Interesting study on immune cell profiling in PsA pts ⭐️variability in T cell sub-populations in PsA pts ⭐️no difference in lymphocyte cell populations before/after therapy Abs#0056 https://t.co/16PYxaxT2S #ACR21 @RheumNow https://t.co/dWaJr7hJ1p

• Peripheral Blood Immune Cell Profiling in Psoriatic Arthritis: Comparison of Pa…

#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19. ▶️150 mg RZB vs Placebo ⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI ⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn ⭐️No safety signal https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd

• https://bit.ly/2ZWO0rV

KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA: 👉phase 3 DBRPCT 24 weeks 👉150 mg week 0,4, 16 weeks 👉improved ACR20,ACR50,ACR70 👉improved PASI90 👉improved HAQ-DI 👉no increased safety signals #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi